Cryofibrinogen is an abnormal protein that forms precipitate only in plasma. Cryofibrinogenaemia (CF) can be detected both in healthy persons and patients with autoimmune diseases, cancer and infections. Essential CF is frequently asymptomatic, although in a proportion of patients it is associated with skin lesions and systemic manifestations and can lead to refractory skin ulcers and gangrene or thrombotic events. Identification of CF in plasma is simple, but establishing a definite diagnosis may be a challenge due to a lack of accepted diagnostic criteria. Several treatment options have been suggested for patients with symptomatic CF, although their efficacy has been shown only in uncontrolled series or case reports. A variety of possible approaches to drug treatment poses additional problems for the physician. Treatment for secondary CF usually relies on effective management of the underlying disease. The clinical significance of CF and its true prevalence are apparently underestimated and should be further studied.
Introduction
In 1955 Korst and Kratochvil [1] identified an abnormal protein that precipitated when cooled and returned to solution at room temperature in the plasma of a patient with migrating thrombophlebitis and lung cancer. By other physical properties, cryoprotein was compatible with fibrinogen and therefore was designated as cryofibrinogen. Cryofibrinogen should be distinguished from cryoglobulin since, unlike the latter, it precipitates only in plasma and not in serum. Cryofibrinogenaemia (CF) can be detected in both healthy persons and patients with different disorders, including autoimmune diseases, cancer, infections, etc. CF remains terra incognita for physicians and does not attract much attention from researchers, although over the last two decades several relatively large series of CF patients have been reported [26] . The clinical significance of CF and its true prevalence are apparently underestimated and should be further studied. Greater awareness of CF is especially important because it is a potentially treatable and reversible condition. This review summarizes the latest information on the biological and clinical features of CF and its diagnosis and treatment.
Prevalence of CF
The data on the epidemiology of CF are relatively scarce and some were published several decades ago. As expected, its prevalence was low in healthy persons and significantly higher in patients with different conditions that can be associated with CF or with signs and symptoms suggestive of cryoproteinaemia (i.e. cold hypersensitivity, skin ulcers, purpura). In two studies, asymptomatic CF was detected in 3% of healthy persons [2, 7] , while in a very large study CF was present in 3.4% of 36 000 blood samples submitted to the hospital clinical laboratory for complete blood counts [8] . Notably, in the latter study, patients with CF had hyperfibrinogenaemia and elevated a 1 -antitrypsin levels and were four to five times more likely to have invasive cancer, a severe thromboembolic event or to die than a random hospital patient, while correlation with infection or sepsis was not found. In a more recent study, 2312 patients were tested for CF in a single university hospital (Pitié -Salpé triè re, Paris) [3] . A total of 515 patients had positive test results, of whom 455 (88.3%) had an associated cryoglobulin. Therefore the prevalence of isolated persistent CF in this study was 2.6%. CF was classified as essential in 36 of 60 (60%) patients. Causes of the secondary CF were variable and included different connective tissue diseases or vasculitides in two-thirds of patients and cancer or infections in one-third of patients. In the other studies, a proportion of patients with essential CF among all identified patients with CF ranged from 30 to 57% [2, 46] . The most common associated diseases in patients with secondary CF were similar in all studies and could be divided into four groups: bacterial and viral infections, autoimmune diseases including vasculitis, lymphoproliferative disorders and solid tumours.
The higher prevalence of CF can be expected in patients with signs and symptoms commonly ascribed to cryoproteinaemia. Blain et al. [2] screened 220 consecutive patients who were referred for an evaluation of features including cold intolerance, recurrent thrombosis, purpura and skin necrosis. CF was detected in 27.3% of patients, although in a significant proportion of these both CF and cryoglobulins were present. Nevertheless, the prevalence of isolated CF was 16.8%. In a similar study, the prevalence of CF was even higher (up to 52%) in 227 patients with acrosyndromes, polyarthralgia and polyalgia, neurological symptoms (suggestive of mononeuritis multiplex or cerebrovascular disease) and skin manifestations (livedo, purpura, urticaria) [6] . Notably, cryoglobulins were detected in only 5 of 227 patients. The same authors also showed a very high prevalence of CF (80%) in 45 patients with primary RP [6] , while Terrier et al. [9] identified positive cryofibrinogen without detectable cryoglobulin in 11% of 101 consecutive patients with different renal disease admitted to a nephrology department. In the latter study, the causes of nephropathy and laboratory parameters (changes in urine and kidney function) did not differ significantly between the groups of patients with and without CF. The presence of CF was not associated with cutaneous manifestations, but increased the risk of frequent severe thrombotic events from 0 to 36% (P < 0.0001). The prevalence of CF was also high (74%) in 50 patients with IgA nephropathy [10] , while the levels of CF were increased in non-traumatic and multifocal osteonecrosis [11] .
Mixed cryoglobulinaemia is a relatively common finding in patients with HCV infection and might cause systemic vasculitis. Delluc et al. [12] studied 143 consecutive HCVinfected patients, including 57 patients with HCV-related vasculitis. Fifty-three of 143 patients (37%) were cryofibrinogen positive, but the majority of these patients (47/53) were also cryoglobulin positive. Therefore the prevalence of isolated CF in this study was only 4.2%; comparable to that in healthy volunteers.
Current data suggest that isolated CF can be detected in up to 3% of healthy donors and unselected patients admitted to the hospital with different diseases. CF is usually asymptomatic, but may be associated with a higher incidence of thrombotic complications. Its prevalence was significantly higher (up to 1752%) in patients with different signs and symptoms suggesting cryoproteinaemia. The high prevalence of CF in patients with primary RP or IgA nephropathy and the increased prevalence in patients with different kidney disorders should be confirmed in further studies.
Pathophysiology
The pathophysiology of CF is not completely understood. CF does not merely reflect high plasma fibrinogen levels, as they were not increased in these patients [2, 6] . The most specific finding on skin biopsy of patients with CF was plugging of the superficial and deep blood vessels with thrombi containing precipitates of cryofibrinogen, which consisted of fibrinogen, fibronectin, a 1 -antitrypsin and a 2 -macroglobulin [2] . Fibronectin probably binds fibrin and fibrinogen and acts as a nucleus for coldinduced precipitation of fibrinogen [13] . Histological data, increased plasma levels of a 1 -antitrypsin and a 2 -macroglobulin, which inhibit fibrinolysis, and a delayed euglobulin lysis time suggest that cryofibrinogen formation and blood clotting can develop as a result of a defect in the fibrinolytic process [3] , although not all studies have detected elevated fibrinolysis inhibitor levels in the plasma of patients with CF [6] . This raises the possibility that other pathophysiological processes may be involved, such as altered thrombin-binding capacity [6, 16] . Thrombotic occlusions of medium and small vessels might be further exacerbated by reflex vasospasm, vascular stasis and hyperviscosity [3, 6] .
Fibronectin can interact with circulating immunoglobulins or immune complexes, which are produced during inflammatory or autoimmune diseases [14, 15] . Histological studies show that CF can be accompanied by variable inflammatory lymphocytic and/or monocytic infiltration and granulomatous vasculitic components [16] . The frequent presence of immunoglobulins within the CF complex when associated with cryoglobulins [2] , the granular deposits of IgM, IgA and C3 [17] or endothelial immune complexes [18] in the vessel walls of patients with CF and reports of anti-fibrinogen antibodies [19, 20] suggest a role for immunological mechanisms. This hypothesis is further supported by the efficacy of immunosuppressive treatment in a proportion of patients with CF.
Additional studies are needed to elucidate the pathophysiology of essential and secondary CF. These data will help to develop the best strategy for treatment, which should be personalized since clinical manifestations of CF cannot be explained by a single mechanism.
Clinical features
The clinical picture of essential and secondary CF was described in several series ranging from 49 to 117 patients (Table 1 ) [26] . The average age of patients at presentation was 4060 years. In all studies there were more females than males. The onset or the exacerbation of the clinical symptoms was frequently reported by patients or physicians to be related to exposure to cold. There are also case reports of complications that developed following superficial cryosurgery, the use of cooling blankets and generalized body cooling during prolonged surgical procedures [21, 22] .
Skin manifestations were present in the vast majority of patients (up to 80%) and included skin necrosis or ulcers, purpura, livedo reticularis and/or RP. In up to 8% of patients, ischaemia led to gangrene, which can require amputation ( Fig. 1 ) [16] . In one study, patients with skin necrosis had significantly higher levels of CF compared with those without necrosis [6] , but the number of cases was small and similar data were not found in another study [4] . Hands, feet, nose, ears and buttocks were more often affected because of their greater sensitivity to cold [16] .
Systemic manifestations such as arthralgia or arthritis, myalgia and fever can occur in 2030% of patients with essential CF [16] . Their frequency was even higher in patients with secondary CF, but this finding was probably due to underlying diseases. Notably, patients with essential CF did not present with low complement C3 or C4 levels, RF, ANAs and aPL or aCL. Mononeuritis multiplex developed in 622% of patients with essential CF. These patients can also present with signs of kidney disease (proteinuria, haematuria and/or kidney failure), but its incidence was low [16] . As noted above, CF can be detected in a significant proportion of patients with different kidney disorders (e.g. IgA nephropathy) [9, 10] , but it is too early to conclude that kidney dysfunction is somehow related to CF, and these finding should be reproduced in additional studies.
The association between CF and thrombotic complications even in the absence of cutaneous or other typical manifestations was first noted several decades ago [8] . Arterial and venous thrombotic events were reported in up to 55% of patients with essential CF [3] , although in the majority of case series they occurred less frequently (4.526%) [2, 4, 6] . Thrombotic complications include cutaneous events, cerebrovascular thrombus, myocardial infarct, superficial and deep vein thrombosis, obstruction of the iliac or femoral artery, pulmonary emboli, mesenteric artery thrombosis and retinal artery thrombosis [23] . In one study, the plasma cryofibrinogen level in patients with thrombosis was two times higher than in those without thrombosis [3] . Similar to disseminated intravascular coagulation, paradoxical spontaneous bleeding may occur due to the depletion of clotting factors [23] .
In conclusion, the majority of patients with CF present with different skin manifestations, including necrosis and refractory ulcers, that may be associated with constitutional symptoms and thrombotic events and less often with nervous system and kidney involvement. The clinical features of essential and secondary CF are similar and the differences between the two conditions reported in certain series were probably related to underlying autoimmune or other conditions.
CF and cryoglobulinaemia
Available evidence suggests that CF is frequently associated with cryoglobulinaemia, though the results of studies have been inconsistent. In the largest study, CF was detected in 515 of 2321 patients tested in a single hospital. Approximately 88% of them were also cryoglobulin positive [3] . In a smaller study, isolated CF, isolated Data collected from published studies [26] .
www.rheumatology.oxfordjournals.org cryoglobulinaemia and combined CF and cryoglobulinaemia were found in 16.9, 4.5 and 10.5% of 220 patients who presented with signs and symptoms suggestive of cryoproteinaemia [2] . Associated cryoglobulinaemia was detected in 23 of 60 patients with CF (38%), while CF was found in 23 of 33 patients (70%) who were cryoglobulin positive. Belizna et al. [4] reported the presence of cryoglobulinaemia in 11 of 59 patients (19%) with CF, while in another study it was present in 47 of 53 cryofibrinogen-positive HCV-infected patients (89%) [12] . The clinical significance of CF combined with cryoglobulinaemia is largely unknown. Michaud et al. [24] detected cryofibrinogen in 18 of 29 patients (62%) with cryoglobulinaemic vasculitis. Median cryoglobulin levels and clinical manifestations were similar in patients with and without CF. However, CF was associated with a higher frequency of cancers and haematological disorders (39 vs 0%; P = 0.026) and more intensive treatment for vasculitis [odds ratio 2.86 (95% confidence interval 1.06, 7.73)]. Blain et al. [2] showed that the most common manifestations were cutaneous in patients with isolated CF and in those with combined CF and cryoglobulinaemia (77 and 58%, respectively). Nevertheless, patients with isolated CF, particularly those without an underlying disease, suffered more frequently from recurrent and necrotic skin lesions mainly triggered by cold exposure, while autoimmune, infectious or malignant diseases were encountered more frequently in patients with combined CF and cryoglobulinaemia (79 vs 47%; P = 0.02).
Thus patients with signs and symptoms suggestive of cryoproteinaemia should be tested for CF and cryoglobulinaemia, as the two conditions are frequently associated with each other. The clinical significance of this association is difficult to estimate due to the lack of evidence, but it probably increases the likelihood of underlying disease that should be identified and treated urgently. In patients with cryoglobulinaemic vasculitis, CF may also worsen clinical manifestations.
Diagnosis of CF
The diagnosis of CF should be suspected in patients with typical skin lesions (e.g. purpura, ulcers or necrosis), especially if associated with constitutional symptoms, arthritis/arthralgia, mononeuritis multiplex and/or thrombotic events. Unlike cryoglobulinaemia, RF is absent. Wellaccepted criteria for the diagnosis of CF are not available. Nevertheless, a compatible clinical presentation and a positive repeated test for cryofibrinogen are usually sufficient to diagnose CF (Table 2 ) [16] . The method of cryofibrinogen detection is described elsewhere [3, 6] . In brief, blood should be collected in pre-warmed tubes containing oxalate, citrate or ethylenediaminetetraacetic acid as the anticoagulant and spun at 37 C within the next hour [16, 23] . Heparin should not be used because of the likelihood of false-positive results. After centrifugation, the plasma and sera are chilled at 4 C for up to 8 days to induce precipitation of cryofibrinogen and cryoglobulin.
Cryofibrinogen dissolves when warmed to 37 C but reprecipitates when recooled to 4 C. If the diagnosis of CF remains uncertain, additional tests should be performed. Supportive evidence can include skin biopsy showing thrombi within the blood vessels and/or signs of inflammation or an angiogram revealing abrupt occlusion of small to medium arteries [16] , though the latter test is probably not needed in the majority of patients.
In at least 3050% of patients CF is a secondary condition that can be associated with variable autoimmune diseases, infections, solid tumours and lymphoproliferative disorders, such as B or T lymphomas, chronic lymphocytic leukaemia, Waldenstrom's macroglobulinaemia or multiple myeloma [16] . Therefore all patients who are cryofibrinogen positive require thorough investigation that should include complete blood count, hepatic and renal function parameters, ANA, ANCA, C3 and C4 fractions, serum protein electrophoresis and immunoelectrophoresis, immunoglobulin assays, haemostasis tests, viral and bacterial serology, a bone marrow biopsy, full-body CT and/or a PET scan [4] . CF may be pseudo-essential in a proportion of cases [5] . In one study after a mean follow-up period of 36 months, 11 of 23 (47%) patients who were initially diagnosed as essential CF were found to have an underlying lymphoma [4] . These patients experienced one or more clinical relapses, had severe cutaneous manifestations at disease onset and developed multiple clinical symptoms, but there was no correlation between cryofibrinogen levels and progression to lymphoma. The initial symptoms of lymphoma were nonspecific (asthenia) and only regular follow-up with a full screening allowed the detection of an underlying tumour. A short delay between the diagnosis of pseudoessential CF and that of lymphoma reduces the likelihood of an accidental association between the two conditions, but these findings were unexpected and should be confirmed in further prospective studies. Currently there are no similar data in the published literature and the prevalence of lymphoma in the other series did not exceed 5% [3] . Soyfoo et al. [6] did not observe the development of lymphoma within a 2 year follow up in > 60 patients with primary CF. Nevertheless, prolonged follow-up of patients with primary CF is essential. Special attention should be paid to signs and symptoms that could be suggestive of lymphoma, such as fever, anorexia, weight loss or enlarged lymph nodes [4] .
The diagnosis of CF is usually not difficult in patients with characteristic skin lesions who test positive for cryofibrinogen and do not have circulating cryoglobulins, although thorough investigation and regular follow-up are required to exclude possible underlying disease that can be detected in up to 50% of cases of CF. Essential or secondary CF should be considered in patients with unexplained thrombotic events, though it might be difficult to establish the association between CF and ischaemic stroke or myocardial infarction in middle-aged or elderly patients with cardiovascular risk factors who do not have other manifestations of CF.
Treatment for CF
The treatment for CF is empiric and non-evidence based. In patients with essential CF, the treatment relies on possible pathophysiologic mechanisms that include impaired fibrinolysis, increased thrombotic activity, inflammation and autoimmunity, while in secondary CF the treatment should be directed towards the underlying disease. Avoidance of exposure to cold is important for all patients [16] , though this recommendation can be difficult to fulfil in countries with cold climates. For treatment decisions in patients with essential CF it is helpful to differentiate thrombotic vasculopathy leading mainly to ischemic complications from vasculitis that indicates a need for immunosuppressive/anti-inflammatory treatment. Patients with essential CF probably require prolonged maintenance treatment since 4276% of them develop relapse within the first year after the onset of symptoms [3, 4] .
Fibrinolytics and activators of fibrinolysis
Some authors suggest that routine use of intravenous streptokinase or other fibrinolytics is justified in patients with CF [24] , though in fact experience with this kind of treatment is quite limited. In the latest case series, Saadoun et al. [3] reported fibrinolytic administration in only 1 of 36 patients with essential CF. A 63-year-old man was referred for multiple arterial and venous thromboses of the legs and severe foot ischaemia. He was treated with warfarin, but developed peripheral gangrene leading to left foot amputation. Daily i.v. administration of alteplase at a low dose (10 mg) led to dramatic clinical improvement and the disappearance of CF. In another case series, the clinical outcome was successful with streptokinase administration in 4 of 61 patients, though the authors did not present full details of the cases [5] . Fibrinolysis may be considered in the acute phase in patients with severe ischaemic manifestations of CF, though the need for i.v. administration limits its use for prolonged treatment. A risk:benefit ratio of fibrinolytics in CF has not been established. Saadoun et al. [3] showed the efficacy of repeated alteplase administration at a dose of 10 mg/ day while the recommended dose of this medication for single administration in acute myocardial infarction is 100 mg [25] . Low-dose administration may improve the safety of thrombolysis, but its efficacy needs to be established.
Stanozolol is a synthetic steroid that is derived from testosterone. It has anabolic and androgenic properties and enhances fibrinolysis. Currently stanozolol is approved for the treatment of hereditary angioedema. Successful treatment with stanozolol (24 mg administered orally twice daily) in patients with essential CF has been described in several case reports [2628] . However, stanozolol is not commonly used in patients with CF. In recent case series, its administration was reported in only one patient [2, 3, 5] . A disadvantage of stanozolol is the high risk of adverse events related to its androgenic activity (e.g. hirsutism, acne, sodium retention, hypertension, hyperlipidaemia).
Antithrombotic agents
The occurrence of arterial and venous thrombotic events in patients with CF justifies maintenance treatment with antithrombotic medications. Patients with venous thrombosis apparently require administration of oral anticoagulants while patients with arterial thrombotic complications should probably be given low-dose aspirin alone or in combination with anticoagulants. Currently it is unknown [23] suggested that aspirin should not be used due a lack of benefit in preventing recurrent skin lesions, but this is controversial [16] . Due to a lack of evidence, it is impossible to draw any conclusions regarding the optimum duration of thromboprophylaxis.
Corticosteroids with or without immunosuppressive agents
Corticosteroids with or without immunosuppressive medications are a mainstay of therapy for secondary CF associated with autoimmune diseases, though they are frequently given to patients with essential CF as well (up to 75% of patients) [2, 3] . Saadoun et al. [3] found that approximately two-thirds of patients with essential CF received an anticoagulation therapy in association with corticosteroids. Complete therapeutic response (i.e. complete clinical improvement with a disappearance of plasma CF) was achieved in 76% of patients, though relapses with plasma CF reappearance occurred in > 40% of cases. The indications for corticosteroid treatment and doses in patients with essential CF are not clearly defined. The use of corticosteroids is justified in patients with fever, arthritis/arthralgia, myalgia, mononeuritis multiplex and/or renal disease. Immunosuppressive agents should be reserved for more severe cases. The results of skin biopsy showing inflammation might be important for deciding on treatment, but correlation of histological data with the outcomes of treatment has not been established. Rituximab was highly effective in patients with severe cryoglobulinaemic vasculitis, but there is no experience with the use of this drug or other biologic agents in patients with essential CF.
Other approaches
Recently, healing of ulcers with colchicine and high-dose pentoxyfiline has been reported in one patient with CF who remained ulcer free for 2 years taking this combination [29] . Blain et al. [2] used colchicine in combination with other medications in 60% of their patients with essential CF. Unfortunately the authors did not comment on the efficacy of this medication, therefore it is reasonable to conclude that it was not very useful. Evidence supporting the use of plasmapheresis in patients with essential CF is scarce, and all the cases were reported a few decades ago [20, 30] . There are no published reports on the use of cryofiltration apheresis in patients with CF.
Conclusion
CF was described >60 years ago but remains a neglected disease. A search in PubMed revealed only a small number of case reports, several case series and a few reviews on this topic (the last one was published 3 years ago [16] ). CF is probably not so uncommon in clinical practice and should be suspected in patients with typical skin lesions, for example, purpura, ulcers or necrosis, especially if associated with constitutional symptoms, arthritis/arthralgia, mononeuritis multiplex and/or thrombotic events. The term CF is misleading, as cryofibrinogen positivity in a majority of patients does not induce any clinical manifestations, therefore cryofibrinogenaemic vasculopathy (or vasculitis) should be identified in cryofibrinogen-positive patients. The available evidence on different aspects of CF is limited and frequently inconsistent or controversial. In patients with secondary CF, effective management of the underlying disease is usually sufficient to achieve improvement, while approaches to treatment for essential CF in reported patients were variable and ranged from avoidance of cold exposure to aggressive immunosuppression and plasmapheresis. Today, the majority of patients with essential CF are treated with corticosteroids (and immunosuppressive medication in more severe cases) in combination with oral anticoagulants and/or low-dose aspirin. The risk of relapse is high and anti-inflammatory therapy may only have a limited impact on the course of thrombotic vasculopathy in the absence of prominent inflammation. Low-dose thrombolysis may be effective in selected patients. Case reports suggest that stanozolol, which enhances fibrinolysis, can be beneficial, but frequent side effects related to androgenic activity limit its use. There is a need to improve the evidence base to address the optimum management of these conditions based on our understanding of the pathogenesis of the disease. We still lack robust pre-clinical/translational research to support a pathogenic role for cryofibrinogen, therefore it is not clear whether CF represents a separate disease entity or epiphenomenon, given the detection of cryofibrinogen in a proportion of the normal population and the lack of a specific clinical phenotype. In patients with the various associated clinical presentations, cryofibrinogen is found in a small proportion, and these symptoms may be attributable to the underlying immune-mediated inflammatory disease in many situations.
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